| 2025-11-21 |
详情>>
股本变动：
变动后总股本615.51万股
|
| 2025-11-21 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.01美元,归母净利润-712.2万美元,同比去年增长35.15%
|
| 2025-08-26 |
复牌提示：
2025-08-25 19:50:00 停牌，复牌日期 2025-08-26 09:00:00
|
| 2025-08-22 |
详情>>
拆分方案：
每4.0000合并分成1.0000股
|
| 2025-08-14 |
详情>>
业绩披露：
2025年中报每股收益-0.01美元,归母净利润-538万美元,同比去年增长28.26%
|
| 2025-05-27 |
股东大会：
将于2025-07-01召开股东大会
会议内容 ▼▲
- (1)To re-elect each of Dr. Nissim Darvish and Ms. Jill Quigley as Class I directors, to hold office until the close of the Company’s annual general meeting of shareholders in 2028, and until their respective successors are duly elected and qualified, or until their respective offices are vacated in accordance with our Articles of Association (the “Articles”) or the Israeli Companies Law, 5759-1999 (the “Companies Law”);
(2)To approve a grant of 75,000 restricted share units (RSUs) to Dr. Adi Mor, the Company’s Chief Executive Officer, Chief Scientific Officer and member of the board of directors;
(3)To approve the re-appointment of Somekh Chaikin, a member firm of KPMG International, as the Company’s independent registered public accounting firm for the year ending December 31, 2025, and until the Company’s next annual general meeting of shareholders, and to authorize the Company’s board of directors (with power of delegation to its audit committee) to set the fees to be paid to such auditors.
|
| 2025-05-15 |
详情>>
业绩披露：
2025年一季报每股收益-0.01美元,归母净利润-332.3万美元,同比去年增长14.09%
|
| 2025-04-04 |
详情>>
业绩披露：
2024年年报每股收益-0.04美元,归母净利润-1394.5万美元,同比去年增长42.43%
|
| 2025-04-04 |
详情>>
业绩披露：
2022年年报每股收益-0.12美元,归母净利润-2764.6万美元,同比去年增长-121.56%
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.04美元,归母净利润-1098.2万美元,同比去年增长47.21%
|
| 2024-11-14 |
财报披露：
美东时间 2024-11-14 盘前发布财报
|
| 2024-08-21 |
详情>>
业绩披露：
2024年中报每股收益-0.03美元,归母净利润-749.9万美元,同比去年增长55.16%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.01美元,归母净利润-386.8万美元,同比去年增长55.81%
|
| 2024-05-03 |
股东大会：
将于2024-06-10召开股东大会
会议内容 ▼▲
- 1.To re-elect each of Dr. Adi Mor and Dr. Alan Moses as Class III directors, to hold office until the close of the Company’s annual general meeting of shareholders in 2027, and until their respective successors are duly elected and qualified, or until their respective offices are vacated in accordance with our Articles of Association (the “Articles”) or the Israeli Companies Law, 5759-1999 (the “Companies Law”).
2.To approve an increase of the Company’s authorized share capital and to amend the Company’s Articles accordingly.
3.To approve the re-appointment of Somekh Chaikin, a member firm of KPMG International, as the Company’s independent registered public accounting firm for the year ending December 31, 2024 and until the Company’s next annual general meeting of shareholders, and to authorize the Company’s board of directors (with power of delegation to its audit committee) to set the fees to be paid to such auditors.
|
| 2024-03-28 |
详情>>
业绩披露：
2023年年报每股收益-0.1美元,归母净利润-2422.1万美元,同比去年增长12.39%
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.09美元,归母净利润-2080.4万美元,同比去年增长-7.38%
|
| 2023-07-03 |
股东大会：
将于2023-08-07召开股东大会
会议内容 ▼▲
- 1.To re-elect each of Dr. Claude Nicaise and Mr. Neil Cohen as Class II directors, to hold office until the close of the Company’s annual general meeting of shareholders in 2026, and until their respective successors are duly elected and qualified, or until their respective offices are vacated in accordance with our Articles of Association or the Companies Law.
2.To approve an amendment to the compensation terms of Dr. Adi Mor in connection with her appointment as the Company’s Chief Executive Officer.
3.To approve amendments to the compensation terms of the non-executive members of the Board of Directors of the Company.
4.To approve the re-appointment of Somekh Chaikin, a member firm of KPMG International, as the Company’s independent registered public accounting firm for the year ending December 31, 2023 and until the Company’s next annual general meeting of shareholders, and to authorize the Company’s board of directors (with power of delegation to its audit committee) to set the fees to be paid to such auditors.
|
| 2022-04-28 |
股东大会：
将于2022-06-07召开股东大会
会议内容 ▼▲
- 1.Election of two Class I directors to serve on our board of directors for a term of three years or until their successors are elected and qualified, for which Dr. Nissim Darvish and Joel Maryles are the nominees.
2.Approval of an amendment to the terms of compensation of Dr. Adi Mor, the Company’s Co-Founder, Chief Scientific Officer and Class III Director.
3.Approval of an amendment to the terms of compensation of Dr. Adi Mor, the Company’s Co-Founder, Chief Scientific Officer and Class III Director.
4.Ratification of the appointment of Somekh Chaikin, a Member Firm of KPMG International, as our independent registered public accounting firm for the year ending December 31, 2022.
|
| 2022-01-05 |
股东大会：
将于2022-02-10召开股东大会
会议内容 ▼▲
- 1.Approval of the appointment of Dr. Dale Pfost, Chief Executive Officer and Class III director of the Company, to the position of Chairman of the Board of Directors of the Company.
|
| 2021-09-17 |
股东大会：
将于2021-10-25召开股东大会
会议内容 ▼▲
- 1.approval by a majority of the ordinary shares or ADSs held and voted at the Special Meeting by non-controlling shareholders who do not have a conflict of interest (referred to under the Israeli Companies Law, 5759-1999 (the “Companies Law) as a “personal interest”) in the approval of the proposal, excluding abstentions;
2.the total number of shares held by non-controlling, disinterested shareholders (as described in the previous bullet-point) and voted against the proposal, does not exceed two percent (2%) of the aggregate voting rights in the Company.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-06-14 |
股东大会：
将于2021-07-19召开股东大会
会议内容 ▼▲
- 1.To approve the Company’s updated Compensation Policy for directors and officers;
2.To approve an amendment to the terms of engagement of Dr. Adi Mor, the Company’s Chief Executive Officer;
3.To approve an increase in the number of ordinary shares reserved for issuance under the Company’s 2015 Share Incentive Plan;
4.To approve the reappointment of Somekh Chaikin, a member firm of KPMG International (“KPMG”) , as our independent auditors and to authorize our board of directors to delegate to the audit committee the authority to fix the said independent auditors’ remuneration in accordance with the volume and nature of their services.
|
| 2021-03-16 |
详情>>
内部人交易：
Cohen Neil Harris股份增加2409.00股
|
| 2021-03-12 |
详情>>
拆分方案：
每16.0000合并分成1.0000股
|
| 2021-02-12 |
股东大会：
将于2021-03-15召开股东大会
会议内容 ▼▲
- 1.To approve the consummation of the Merger and the other transactions contemplated by the Merger Agreement, including the issuance of Anchiano ordinary shares, to be represented by ADSs, at the effective time of the Merger to the securityholders of Chemomab;
2.To approve the issuance of such number of Anchiano ordinary shares (including ordinary shares represented by ADSs) in the private placement financing, as described in this proxy statement/prospectus, as would yield at least $30.0 million and up to $50.0 million of aggregate gross proceeds to Anchiano;
3.To approve and adopt Anchiano’s amended and restated articles of association, attached as Annex E to this proxy statement/prospectus, or the Amended and Restated Articles of Association, effective upon the effective time of the Merger, which among other things will (i) increase the registered share capital of Anchiano from 500,000,000 ordinary shares, without par value, to 650,000,000 ordinary shares, without par value, (ii) effect the Reverse Split, at a ratio in the range of between 1-for-2 to 1-for-4, inclusive, with such ratio to be determined in the discretion of Anchiano’s board of directors, (iii) amend the manner in which directors are elected to a classified board format, (iv) change the name of Anchiano from “Anchiano Therapeutics Ltd.” to “Chemomab Therapeutics Ltd.” or such other name as may be approved by Chemomab and the Israeli Registrar of Companies and (v) make such other changes as are set forth in the Amended and Restated Articles of Association;
4.To approve the form of indemnification agreement for directors and officers of Anchiano, attached as Annex F to this proxy statement/prospectus, or the Indemnification Agreement, effective upon the effective time of the Merger, and to authorize the execution and delivery of such Indemnification Agreement with all directors of Anchiano to be in office immediately following the effective time of the Merger or thereafter elected or appointed to the board of directors of Anchiano;
5.To approve an amendment to Anchiano’s Compensation Policy to remove the limit on the annual premium for directors and officers insurance;
6.To approve an amendment to the compensation terms of the current and future directors of Anchiano, and related amendments to Anchiano’s Compensation Policy;
7.To transact any other business that may be properly brought before the meeting or any continuation, adjournment or postponement thereof.
|
| 2020-04-06 |
股东大会：
将于2020-04-23召开股东大会
会议内容 ▼▲
- 1.To elect to the Board of Directors of the Company (the “Board” or the “Board of Directors”) the eight director nominees named in the enclosed proxy statement to serve until the next annual general meeting of shareholders and until their successors have been duly elected and qualified;
2.To approve the Company’s Compensation Policy for directors and officers, reflecting certain amendments to the Compensation Policy;
3.To approve amendments to the Company’s Articles of Association to (i) increase our authorized share capital from 100,000,000 ordinary shares, with no par value each, to 500,000,000 ordinary shares, with no par value each and (ii) amend the quorum requirement for meetings of the Company’s shareholders;
4.To approve the reappointment of Somekh Chaikin, a member of KPMG International, as our independent auditors and to authorize our board of directors to delegate to the audit committee the authority to fix the said independent auditors’ remuneration in accordance with the volume and nature of their services;
5.To report on the business of the Company for the fiscal year ended December 31, 2019, including a review of the fiscal 2019 financial statements;
6.To act upon any other matters that may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2019-05-28 |
股东大会：
将于2019-07-02召开股东大会
会议内容 ▼▲
- 1.to reelect Dr. Frank G. Haluska, Dr. Stephen J. Hoffman, Mr. Robert T. Connelly, Mr. Reginald L. Hardy, Dr. Lawrence Howard, Mr. Isaac T. Kohlberg and Mr. Dennison T. Veru as our directors;
2.to approve the compensation payable to our directors;
3.to approve the compensation package payable to Dr. Frank G. Haluska, our Chief Executive Officer;
4.to approve an amendment to our Compensation Policy, regarding the vesting schedule of equity grants to our directors and certain executive officers;
5.to approve the reappointment of Somekh Chaikin, a member of KPMG International, as our independent auditors, and to authorize our board of directors to delegate to the audit committee the authority to fix the said independent auditors' remuneration in accordance with the volume and nature of their services;
6.to report on the business of the Company for the fiscal year ended December 31, 2018, including a review of the fiscal 2018 financial statements;
7.to act upon any other matters that may properly come before the Annual Meeting or any adjournment or postponement thereof.
|